VK2735 is a dual GLP-1/GIP medicine, the same class as Eli Lilly's Zepbound ... that also aced phase 2 studies. Viking Therapeutics Inc dominated the market today, gaining €0.97 (3.200%). With 6 Buy ...

Its product portfolio includes the first and only approved oral precision medicine to treat Fabry ... so we initiated a position.” Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage ...

Introduction Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and chronic ...

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against the other stocks. Wall Street's major indices kicked off the trading on a positive note ...

In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other stocks that took a nosedive in January. Historically, the S&P 500’s performance ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) shares traded down 4.9% on Monday after Maxim Group lowered their price target on the stock from $120.00 to $70.00.Maxim Group currently ...

KBC Group NV grew its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 41.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC.

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

We recently published an article titled These 10 Companies Led Monday's Downturn. In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against the other ...